miRNAs; a novel strategy for the treatment of COVID-19 by Ying, H. et al.
Cell Biol Int. 2021;1–9. wileyonlinelibrary.com/journal/cbin © 2021 International Federation for Cell Biology | 1
Received: 16 March 2021 | Revised: 8 May 2021 | Accepted: 17 June 2021
DOI: 10.1002/cbin.11653
M IN I ‐R EV I EW
miRNAs; a novel strategy for the treatment of COVID‐19
Hao Ying1 | Mohsen Ebrahimi2 | Mona Keivan3 | Seyed Esmaeil Khoshnam4 |
Sarvenaz Salahi5 | Maryam Farzaneh3
1Zhuji People's Hospital of Zhejiang Province,
Zhuji Affiliated Hospital of Shaoxing
University, Zhuji, China
2Neonatal and Children's Health Research
Center, Golestan University of Medical
Sciences, Gorgan, Iran
3Fertility, Infertility and Perinatology
Research Center, Ahvaz Jundishapur
University of Medical Sciences, Ahvaz, Iran
4Persian Gulf Physiology Research Center,
Medical Basic Sciences Research Institute,
Ahvaz Jundishapur University of Medical
Sciences, Ahvaz, Iran
5Minimally Invasive Surgery Research Center,
Iran University of Medical Sciences,
Tehran, Iran
Correspondence
Hao Ying, Zhuji People's Hospital of Zhejiang
Province, Zhuji Affiliated Hospital of Shaoxing
University, Zhuji 311800, China.
Email: yingyuhan2018@163.com
Maryam Farzaneh, Fertility, Infertility and
Perinatology Research Center, Ahvaz
Jundishapur University of Medical Sciences,
Ahvaz, Iran.
Email: Maryamfarzaneh2013@yahoo.com
Abstract
Coronavirus disease 2019 (COVID‐19) is the seventh member of the bat severe
acute respiratory syndrome family. COVID‐19 can fuse their envelopes with
the host cell membranes and deliver their genetic material. COVID‐19 attacks the
respiratory system and stimulates the host inflammatory responses, enhances the
recruitment of immune cells, and promotes angiotensin‐converting enzyme
2 activities. Patients with confirmed COVID‐19 may have experienced fever, dry
cough, headache, dyspnea, acute kidney injury, acute respiratory distress syn-
drome, and acute heart injury. Several strategies such as oxygen therapy, venti-
lation, antibiotic or antiviral therapy, and renal replacement therapy are commonly
used to decrease COVID‐19‐associated mortality. However, these approaches
may not be good treatment options. Therefore, the search for an alternative‐novel
therapy is urgently important to prevent the disease progression. Recently, mi-
croRNAs (miRNAs) have emerged as a promising strategy for COVID‐19. The
design of oligonucleotide against the genetic material of COVID‐19 might
suppress virus RNA translation. Several previous studies have shown that
host miRNAs play an antiviral role and improve the treatment of patients with
COVID‐19. miRNAs by binding to the 3′‐untranslated region (UTR) or 5′‐UTR of
viral RNA play an important role in COVID‐19‐host interplay and viral replication.
miRNAs interact with multiple pathways and reduce inflammatory biomarkers,
thrombi formation, and tissue damage to accelerate the patient outcome. The
information in this review provides a summary of the current clinical application of
miRNAs for the treatments of patients with COVID‐19.
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Abbreviations: ACE2, angiotensin‐converting enzyme 2; ACI, acute cardiac injury; ADAM17, ADAM metallopeptidase domain 17; AKI, acute kidney injury; antimiR, antagonist miR; ARDS,
acute respiratory distress syndrome; cc‐miR, complete complementary miRNA; COVID‐19, coronavirus disease 2019; CSF1 gene, colony‐stimulating factor 1; EVs, extracellular vesicles; Exp5,
exportin‐5; GO, gene ontology; IL‐1, interleukin‐1; LncRNAs, long noncoding RNAs; miRNAs, microRNAs; mRNAs, messenger RNAs; Pre‐miRNA, precursor miRNA; Pri‐miRNAs, primary
miRNAs; RISC, RNA‐induced silencing complex; SARS, severe acute respiratory syndrome; TLR, Toll‐Like receptors; TMPRSS2, Type II transmembrane serine proteases.; TNF, tumor necrosis
factor; TRBP, transactivating response RNA‐binding protein.
1 | INTRODUCTION
Coronavirus disease 2019 (COVID‐19) for the first time emerged in
Wuhan (the capital of central China's Hubei province) and later
spread worldwide (Bernheim et al., 2020; Diao et al., 2020; Lauer
et al., 2019). COVID‐19 has been reported as the seventh member of
the bat severe acute respiratory syndrome (SARS) family, which is
known as SARS‐CoV‐2 (Lauer et al., 2019; Wang et al., 2020; Zhu
et al., 2020). Coronaviruses are enveloped positive‐sense RNA
viruses that generally cause mild to acute respiratory infection in
various species from bats to humans (Chang et al., 2020; Chen, 2020;
Fung et al., 2020; Song, 2020). COVID‐19 contains four structural
proteins, including nucleocapsid (N) protein and membrane (M), spike
(S), and small envelope (E) glycoproteins (Abu‐Izneid et al., 2020).
These viruses directly fuse to the plasma membrane, deliver their
genetic materials, and complete their life cycle (Cascella et al., 2020;
Jan & Arif, 2020). Initial symptoms for most patients with COVID‐19
include fever, headache, shortness of breath, muscle soreness, spu-
tum production, dyspnea, diarrhea, nausea, and fatigue (Bernheim
et al., 2020; Huang et al., 2020; Jiang et al., 2020; Kui et al., 2020).
A slight decrease in platelet levels and a massive release of tumor
necrosis factor (TNF), plasminogen activators, and interleukin‐1 and
6 (IL‐1 and IL‐6) have been reported to stimulate acute endothelial
cell activation and microthrombus in lung vascularity (Schultz
et al., 2021). COVID‐19 infects the respiratory system, triggers
widespread inflammation, promotes the recruitment of immune cells,
and angiotensin‐converting enzyme 2 (ACE2) activities (Abdi, 2020;
Lauer et al., 2019). In a subset of high‐risk patients (patients with
diabetes or preexisting cardiovascular diseases or hypertension),
acute cardiac injury, acute kidney injury, acute respiratory distress
F IGURE 1 miRNA at cellular level due to
COVID‐19 infection. RNA polymerase II or III
transcribed miRNA genes and generates
pri‐miRNAs (primary miRNAs). Subsequently,
Drosha/DGCR8 holoenzyme (microprocessor
cleavage) mediates processing of the pri‐miRNA
to generate the precursor miRNA (pre‐miRNA) or
a hairpin structured precursor (∼60‐ to 70 nt) in
the nucleus. The pre‐miRNAs by Exportin‐5
(Exp5) and Ran‐GTP (a nucleocytoplasmic
transporter) are delivered to the cytoplasm. The
pre‐miRNAs hairpin cleaved into a ∼22
nucleotide duplex through Dicer (RNase III
endonuclease) with the transactivating response
RNA‐binding protein (TRBP) to form a mature
microRNA duplex. The mature miRNAs are
created via RNA‐induced silencing complex.
miRNA binds with the AGO protein
(RNA‐induced silencing complex [RISC]) to
target messenger RNA (mRNA) and trigger
mRNA cleavage, mRNA degradation, and
translation repression. COVID‐19 contains four
structural proteins, including nucleocapsid (N)
protein and membrane (M), spike (S), and small
envelope (E) glycoproteins. miRNAs by binding to
the coding region or 5′‐UTR of viral RNA play an
important role in COVID‐19‐host interplay and
viral replication. COVID‐19, coronavirus disease
2019; miRNA, microRNA; UTR, untranslated
region
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syndrome (ARDS), and multiple organ dysfunction might be triggered
(Chen et al., 2020; Huang et al., 2020; Xu et al., 2020).
Till now, various therapeutic modalities such as antibiotic ther-
apy, antiviral therapy, glucocorticoids therapy, invasive and non-
invasive ventilation, and renal replacement therapy have been
assessed in clinical settings for COVID‐19 patients (Chen et al., 2020;
Chen et al., 2020; Heymann & Shindo, 2020; Huang et al., 2020;
MacLaren et al., 2020; Wang et al., 2020; Zhou et al., 2020). How-
ever, these strategies are not likely to be safe and effective treat-
ment options against COVID‐19 (Jean et al., 2020; Momekov &
Momekova, 2020). Therefore, the search for an alternative‐novel
therapy is urgently important to prevent the disease progression
(Widiasta et al., 2020). Recently, microRNAs (miRNAs) have been
emerged as antiviral regulators of viral genes (Gong & Zhang, 2020;
Huang et al., 2021; Ramaiah, 2020). miRNAs through silencing genes
play an important role in controlling the expression of transcription
factors (Waheed & Zeng, 2020). Hence, it may be feasible to use
miRNAs to overcome COVID‐19 (El‐Nabi et al., 2020; Mishra
et al., 2020). miRNA‐based therapeutic is a promising approach
against heart failure or cardiovascular diseases, neurological dis-
orders, tumorigenesis, and viral infection (Condrat et al., 2020; Cui
et al., 2021; Takahashi et al., 2019). The design of oligonucleotide
against the genetic material of COVID‐19 might suppress virus RNA
translation (Hassab Elnabi, 2020; Yu et al., 2020). Recent evidence
suggests that miRNAs can improve the treatment of patients with
COVID‐19 (El‐Nabi et al., 2020; Garg et al., 2021; Hassab Elna-
bi, 2020; Schultz et al., 2021). The information in this review provides
a summary of the current clinical application of miRNAs for the
treatments of patients with COVID‐19.
2 | THE CANONICAL miRNA BIOGENESIS
miRNAs are a family of noncoding RNAs with an average of 22 nu-
cleotides that interact with messenger RNAs (mRNAs) and play cri-
tical roles in controlling gene expression in a variety of biological
processes (DeVeale et al., 2021). In most cases, miRNAs by miRNA‐
binding sites in the 3′‐untranslated region (UTR) of the target
mRNAs stimulate mRNA degradation and regulate posttranscrip-
tional expression (Valinezhad Orang et al., 2014). Besides, miRNAs
can bind with the 5′‐UTR, gene promoters, and coding sequence
(O'Brien et al., 2018).
RNA polymerase II or III transcribed miRNA genes and gen-
erates pri‐miRNAs (primary miRNAs) (Borchert et al., 2006; Gregory
et al., 2005). Subsequently, Drosha/DGCR8 holoenzyme (micro-
processor cleavage) mediates processing of the pri‐miRNA to gen-
erate the precursor miRNA (pre‐miRNA) or a hairpin structured
precursor (∼60 to 70 nt) in the nucleus (Zeng et al., 2017). The pre‐
miRNAs by Exportin‐5 (Exp5) and Ran‐GTP (a nucleocytoplasmic
transporter) are delivered to the cytoplasm (Wu et al., 2018).
The pre‐miRNAs hairpin cleaved into a ∼22 nucleotide duplex
through Dicer (RNase III endonuclease) with the transactivating
response RNA‐binding protein to form a mature miRNA duplex
(Fareh et al., 2016; Graves & Zeng, 2012; Ha & Kim, 2014). The
mature miRNAs are created via RNA‐induced silencing complex
(RISC) (Berezikov et al., 2007; Du & Zamore, 2005; Ruby et al., 2007).
miRNA binds with the AGO protein (RISC) to target mRNA and
trigger mRNA cleavage, mRNA degradation, and translation repres-
sion (Lam et al., 2015; Pu et al., 2019) (Figure 1). It is now accepted
that the epigenetic modulation of miRNA expression plays an im-
portant role in several pathological processes after viral infections.
3 | THE POTENTIAL FUNCTION OF
miRNAs FOLLOWING COVID‐19 INFECTION
Growing evidence shows that the host‐encoded miRNAs could
modulate virus replication and pathogenesis (Khan et al., 2020;
Tribolet et al., 2020; Wong et al., 2020; Zhang et al., 2020; Zheng
et al., 2020). miRNAs through binding with viral RNA interact with
different species or strain of viruses (Križnik et al., 2020; Trobaugh
& Klimstra, 2017). miRNAs by binding to the 3′‐UTR (El‐Nabi
et al., 2020; Liu et al., 2017) or 5′‐UTR of viral RNA play an im-
portant role in COVID‐19‐host interplay and viral replication
(Demirci & Adan, 2020; Nersisyan et al., 2020). miRNAs inhibited
tissue damage and coagulation disturbs by suppressing coagulation
cascade, cell death genes, and inflammatory agents in severe
COVID‐19 patients (Schultz et al., 2021).
Table 1 shows the most important miRNAs from the scientific
literature that might act as good targets for COVID‐19 drug
development.
Schultz et al. (2021) revealed that the MSCs‐derived extra-
cellular vesicles could carry small and long noncoding RNAs and
regulate the behavior of target cells. Their results showed that var-
ious miRNAs were associated with exacerbated cytokines and che-
mokines (258 miRNAs), cell death genes (266 miRNAs), and
coagulation cascades (148 miRNAs) (Schultz et al., 2021). Based on
their analysis, miR‐125a‐3p binds to the 3′‐UTR region of TNF,
CXCL10, IL2, IL7, IL10, IL15, and Factor XIII gene. miR‐125a‐3p re-
duces the systemic inflammation, coagulation disturbs, and cell death
in severe COVID‐19 patients. miR‐125b‐1‐3p is another isoform that
targets the 3′‐UTR region of the TNF, interferon (IFN), CCL3,
CXCL10, IL10, IL17A, IL18, IL33, Factor III, IX, XIII, and GSDME
genes. miR‐769‐3p and miR‐202‐3p by targeting the 3′‐UTR region
of the TNF and IFN genes can decrease the cell death and tissue
damage. In severe COVID‐19 ICU patients, let‐7e‐5p by targeting the
3′‐UTR region of the IL1A, IL1B, IL6R, IL10, IL15, TNF, RIPK1,
CASP8, Factor VIII, and CSF3 genes could reduce the coagulation
activation and cell death (Schultz et al., 2021).
Garg et al. (2021) evaluated changes in five circulating cardio-
vascular miRNAs, including miR‐21 (fibrosis‐associated miRNA),
miR‐126 (endothelial miRNA), miR‐155 (cardiovascular disease and
inflammation‐associated miRNA), miR‐208a (myocyte‐associated
miRNA), and miR‐499 (myocyte‐associated miRNA) in patients with
mechanically‐ventilated COVID‐19. They found that serum con-
centration of four miRNAs such as miR‐21, miR‐155, miR‐208a, and
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TABLE 1 The most important miRNAs that might act as good targets for COVID‐19 drug development
miRNAs Target Result Ref.
miR‐125a‐3p TNF, CXCL10, IL2, IL7, IL10, IL15, and
Factor XIII
Reduces the systemic inflammation,
coagulation disturbs, and cell death
(Schultz et al., 2021)
miR‐125b‐1‐3p TNF, IFN, CCL3, CXCL10, IL10, IL17A, IL18,
IL33, Factor III, IX, XIII, and GSDME
miR‐769‐3p TNF and IFN Decrease the cell death and tissue damage
miR‐202‐3p
let‐7e‐5p IL1A, IL1B, IL6R, IL10, IL15, TNF, RIPK1,
CASP8, Factor VIII, and CSF3
Reduces the coagulation activation and cell
death
miR‐21 Myocardial/cardiomyocyte cells Enhance endothelial cell dysfunction,
inflammation, and myocardial damage
(Garg et al., 2021)
miR‐155
miR‐208a
miR‐499
miR‐126 Endothelial cells Protecting from endothelial damage
has‐miR‐17‐5p Antiviral effect during host infection (Khan et al., 2020)
has‐miR‐20b‐5p
hsa‐miR323a‐5p
miR‐18 ACE2 Kidney problems (Widiasta et al., 2020)
miR‐1207‐5p CSF1 Enhances macrophage recruitment and the
acute inflammatory response
(Bertolazzi et al., 2020)
hsa‐miR‐588, hsa‐miR‐587,
and hsa‐miR‐582‐5p
ACE2 Enhance lung pathogenesis and injury (Kim et al., 2020)
hsa‐miR‐221‐3p and
hsa‐miR‐95‐5p
ADAM17
hsa‐miR‐140‐3p and
hsa‐miR‐1255b
TMPRSS2
miR‐5197–3p, miR‐4778‐3p,
and miR‐6864‐5p
The KEGG and GO pathways Increases the pathogenicity (Arisan et al., 2020)
miR‐8066 The KEGG pathway, TGF‐beta signaling, PRLR,
CXCL6, IL6, IL17, and ACVR1 genes
miR‐5197‐3p Enhances the interaction of cc‐miR2 with
the gRNA
Decreases the pathogenicity (Ivashchenko
et al., 2020)
hsa‐let‐7a‐g/i TMPRSS2 Regulation of viral receptor and the host
immunity
(Pontecorvi
et al., 2020)
hsa‐miR‐98‐5p TMPRSS2
hsa‐miR‐145 ADAM17
hsa‐miR‐222 ADAM17
hsa‐miR‐19a/b‐3p Furin
hsa‐miR‐20b Furin
hsa‐miR‐106a Furin
hsa‐miR‐4661‐3p 3′‐UTR of the S gene Inhibits the viral gene expression (Liu et al., 2020)
MR147‐3p TMPRSS2 Enhances the gastrointestinal infection
Abbreviations: ACE2, angiotensin‐converting enzyme 2; ADAM17, ADAM metallopeptidase domain 17; cc‐miR2, cc‐miR for COVID‐19;
CSF1, colony‐stimulating factor 1; GO, gene ontology; gRNA, mRNA of the COVID‐19 genome; miRNA, microRNAs; TGF, transforming growth factor;
TMPRSS2, Type II transmembrane serine proteases.
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miR‐499 were significantly increased in COVID‐19 patients.
Whereas serum concentration of miR‐126 (protective from en-
dothelial damage) was significantly reduced compared to healthy
controls. According to previous studies, miR‐21 and miR‐126 parti-
cipate in endothelial cell dysfunction, miR‐155 stimulates in-
flammation, and miR‐208a and miR‐499 are associated with
myocardial/cardiomyocyte damage (Garg et al., 2021; Hartmann
et al., 2016). Hence, the upregulation of these miRNAs might be a
predictor of inflammation and myocardial damage (Garg et al., 2021).
Khan et al. (2020) showed that three host miRNAs, including has‐
miR‐17‐5p, has‐miR‐20b‐5p, and hsa‐miR‐323a‐5p had an antiviral ef-
fect against COVID‐19. They suggested that miRNAs may specifically
inhibit several Toll‐Like receptors pathways to modulate the host an-
tiviral defense mechanism. Guterres et al. (2020) followed different
stages of COVID‐19 infection and found some miRNAs for positive‐
sense viral RNA (34 miRNA) and negative‐sense (45 miRNAs) that
target the key COVID‐19 genes. Bertolazzi et al. (2020), reported that
COVID‐19 as an exogenous competing RNA could upregulate the ex-
pression of miR‐1207‐5p. In severe COVID‐19, miR‐1207‐5p by tar-
geting the CSF1 gene (colony‐stimulating factor 1 or macrophage
colony‐stimulating factor) enhanced macrophage recruitment and the
acute inflammatory response. Although decrease in ACE2 as a trans-
membrane protein is critical in ARDS pathogenesis (Imai et al., 2005),
previous studies demonstrated that ACE2 is responsible for various
indications of COVID‐19 and kidney problems (Hardenberg &
Luft, 2020; Perico et al., 2020). Widiasta et al. (2020) illustrated that
miR‐18 (miRNA in nephropathy) can regulate ACE2 expression fol-
lowing COVID‐19 infection. Therefore, miR‐18 may be a suitable target
for the kidney pathogenesis of COVID‐19 and ACE2 related diseases.
Nersisyan et al. (2020) evaluated the interaction of six miRNAs, in-
cluding miR‐21‐3p, miR‐195‐5p, miR‐16‐5p, miR‐3065‐5p, miR‐424‐5p,
and miR‐421 with human COVID‐19 RNAs. They suggested that the
expression of miR‐21‐3p was significantly increased in mouse lungs
fallowing infection. Hosseini Rad andMcLellan (2020) observed that the
expression of miR‐197‐5p was upregulated in patients with cardiovas-
cular disease. Therefore, these patients were more susceptible to
COVID‐19 infection. Arisan et al. (2020) illustrated that seven miRNAs,
including miR‐8066, miR‐5197, miR‐3611, miR‐3934‐3p, miR‐1307‐3p,
miR‐3691‐3p, and miR‐1468‐5p by targeting the KEGG pathways in-
creased viral pathogenicity and host responses. They found that miR‐
5197‐3p, miR‐4778‐3p, and miR‐6864‐5p influenced on the gene on-
tology and KEGG pathways, and significantly promoted COVID‐19
pathogenesis. They also reported that miR‐8066 by targeting the KEGG
pathway, TGF‐beta signaling, PRLR, CXCL6, IL6, IL17, and ACVR1
genes increased the pathogenicity of COVID‐19. So, these pathways
may help to assess better therapeutic in COVID‐19‐infected patients.
Ivashchenko et al. (2020) found that synthetic miRNAs such as
complete complementary miRNA (cc‐miR as therapeutic agents can
be used to inhibit the reproduction of the virus. They revealed that
out of 2565 miRNAs, miR‐4778‐3p, miR‐6864‐5p and miR‐5197‐3p
were the most effectively interacting with the gRNA of SARS‐CoV,
MERS‐CoV, and COVID‐19, respectively. miR‐5197‐3p enhanced the
interaction of cc‐miR2 (cc‐miR for COVID‐19, 25 nt) with the mRNA
of the COVID‐19 genome, without side effects on the host genome
or competition with other sides.
Fulzele et al. (2020) assumed that some of the human miRNAs
downregulated with aging which might affect COVID‐19‐host cell
interaction and enhance severity and mortality among adult in-
dividuals more than 65 years with COVID‐19. Kim et al. (2020) ex-
amined on hamster lung tissues infected by COVID‐19 and showed
that five miRNAs, including hsa‐miR‐15a‐5p, hsa‐miR‐15b‐5p, hsa‐
miR‐195‐5p, hsa‐miR‐16‐5p, and hsa‐miR‐196a‐1‐3p could bind to
COVID‐19. Besides, seven miRNAs were found to bind to the ACE2
(hsa‐miR‐588, hsa‐miR‐587, and hsa‐miR‐582‐5p), ADAM17 (ADAM
metallopeptidase domain 17) (hsa‐miR‐221‐3p and hsa‐miR‐95‐5p),
and type II transmembrane serine proteases (TMPRSS2) (hsa‐miR‐
140‐3p and hsa‐miR‐1255b) receptor proteins. They also found that
levels of expression of five miRNAs, including hsa‐miR‐15b‐5p, hsa‐
miR‐195‐5p, hsa‐miR‐221‐3p, hsa‐miR‐140‐3p, and hsa‐miR‐422a
altered after infection. They suggested that hsa‐miR‐15b‐5p and hsa‐
miR‐195‐5p may be suitable therapeutic biomarkers for COVID‐19.
Mukhopadhyay et al. (2020) determined novel hypothalamic
miRNAs that targeting to the ACE2 (31 miRNAs) and TMPRSS2 (29
miRNAs) genes. Therefore, these miRNAs via regulation of ACE2 and
TMPRSS2 expression can be used to treat neurological symptoms in
COVID‐19 patients.
Li et al. (2020) evaluated the expression of miRNAs in the per-
ipheral blood from patient with COVID‐19. They found that the ex-
pression of some miRNAs was increased (35 miRNAs) or decreased
(38 miRNAs). Besides, the expression of three miRNAs, including
miR‐183‐5p, miR‐627‐5p, and miR‐144‐3p was significantly decreased.
Pontecorvi et al. (2020) reported that the sex hormones in human
host cells play important roles in COVID‐19 lethality. They presented
seven gender‐associated miRNAs, including hsa‐let‐7a‐g/i, hsa‐miR‐
98‐5p, hsa‐miR‐145, hsa‐miR‐222, hsa‐miR‐19a/b‐3p, hsa‐miR‐20b,
and hsa‐miR‐106a, which were localized on the X‐chromosome and
participated in regulation of COVID‐19 receptors and host immunity.
These miRNAs were reported to target the TMPRSS2, ADAM17, and
Furin genes. Several hormones such as Estrogen/Erα, progesterone,
androgen, Vitamin D, and 17β‐Estradiol have been already identified
that control the expression of these miRNAs.
Liu et al. predicted that hsa‐miR‐4661‐3p could bind at the po-
tential 3′‐UTR of the S gene of COVID‐19 and repressed the viral
gene expression. In addition, MR147‐3p as a virus‐encoded miRNA
increased the expression of TMPRSS2 and the gastrointestinal in-
fection of COVID‐19 (Liu et al., 2020). Therefore, miRNA can be a
potent diagnostic biomarker for COVID‐19 (Chauhan et al., 2020;
Greco et al., 2020).
4 | LIMITATIONS OF miRNAs AGAINST
COVID‐19
miRNAs are an attractive therapeutic target that would facilitate
the diagnosis and treatment of COVID‐19 infection (Abu‐Izneid
et al., 2020; Canatan et al., 2020; Pierce et al., 2020). miRNAs as
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potent epigenetic regulators stimulate the innate and adaptive im-
mune system and influence the viral propagation (Mukhopadhyay &
Mussa, 2020). However, different sets of miRNAs are expressed in
the host system which target an entire immune pathway (Cho
et al., 2020; Jia & Wei, 2020). Also, various miRNAs with multi‐step
maturation need several strategies to enhance miRNAs function and
develop miRNAs‐based therapeutics against COVID‐19 (Abu‐Izneid
et al., 2020). Besides, manipulating endogenous miRNA to reduce the
risk of COVID‐19 infection may cause negative effects on the
host genome (Ivashchenko et al., 2020; Mishra et al., 2020). Recently,
the viral‐encoded miRNAs have been shown to target several
signaling pathways and critical cellular processes such as transcrip-
tion, metabolism, and defense (Demirci & Adan, 2020; Mishra
et al., 2020).
Demirci and Adan (2020) provided a list of miRNAs which in-
volved in host‐COVID‐19 interaction. They assumed that the
gonadotropin‐releasing hormone receptor, Wnt, EGF, FGF, CCKR,
and PDGF signaling pathways might be influenced by viral miRNA.
Yu et al. (2020) used miRNA precursor prediction tools and identified
location of three novel coronavirus miRNA precursors, including
miR‐P1‐3p (first, second, and third). The COVID‐19‐encoded miRNAs
as autocrine or paracrine agonists of host cells increased nuclear
factor kappa B activity and stimulated proinflammatory cytokines
(Arisan et al., 2020). Therefore, further investigation is required to
identify specific miRNAs that target and stop virus‐induced infection
(Farshbaf et al., 2020; Pontecorvi et al., 2020).
5 | FUTURE STRATEGY USING miRNAs
AGAINST COVID‐19
Several previous studies identified the interactions between miRNA
and SARS‐CoV‐2 and reported novel approaches against SARS‐CoV‐2
infection (Rizkita & Astuti, 2021). It has also been reported that an-
tiviral miRNAs (miR‐24, miR‐124, and miR‐744) by targeting the p38
MAPK pathway play an important role against respiratory virus in-
fection (McCaskill et al., 2017). Although current strategies using
miRNAs for treating COVID‐19 are limited, potential binding sites on
COVID‐19 may highlight the roles of miRNAs in regulating COVID‐19
infections (Alam & Lipovich, 2021; Hum et al., 2021). miRNAs have
been shown to interact with the viral genome, affect vital processes,
regulate the host's cellular microenvironment and the innate immune
network (Demongeot & Seligmann, 2020; Hum et al., 2021). Recently,
two approaches for miRNA‐targeted therapy by the use of miRNA
antagonists or inhibitors (Cobomarsen, an inhibitor of miR‐155) (Seto
et al., 2018) and miRNA mimics (Remlarsen, a miR‐29 mimic) (Gallant‐
Behm et al., 2019) were found to support the efficient expression of
proteins in the host and decrease the negative effects of miRNAs on
the host cells (Gasparello et al., 2021). Miravirsen is a miR‐122 an-
tagonist and the first miRNA‐based drug, which downregulates viral
RNA levels (Santaris Pharma A/S, Phase II clinical trial) (Janssen
et al., 2013; Okuyan & Begen, 2021). Therefore, antagonist miR (an-
timiR) and miR mimic could be innovative approach for the treatment
of COVID‐19 infections (Rizkita & Astuti, 2021). However, miRNA‐
COVID‐19 interaction is a complex process that may enhance or
suppress viral replication (El‐Nabi et al., 2020; Fani et al., 2021).
Among the current efforts for the treatment of COVID‐19, re-
cent experiments developed animal models for COVID‐19 to accel-
erate the preclinical testing of vaccines (Muñoz‐Fontela et al., 2020).
Corbett et al. (2020) assessed the mRNA‐1273 vaccine against
COVID‐19 and showed rapid protection in the upper and lower
airways in nonhuman primates. Despite the challenges of safe and
effective vaccine manufacturing (Forman et al., 2021; Heaton, 2020),
in the case of miRNA‐COVID‐19 interaction, further experimental is
still required to generate miRNA‐based animal models of COVID‐19
to improve vaccine efficacy.
6 | CONCLUSION
COVID‐19 infection stimulates inflammation and endothelial cell
damage in multiorgans with cardiac injury (Garg et al., 2021).
Viruses‐derived miRNA can impact the host miRNA expression level
and improve virus pathogenicity (Abu‐Izneid et al., 2020). Host‐
derived miRNAs play essential roles in limiting viral replication
(Barbu et al., 2020; Wong et al., 2020). There is evidence that
miRNAs are able to downregulate the viral replication, modulate
viral infectious progress, and enhance the survival rates in severe
COVID‐19 patients (Schultz et al., 2021). miRNAs interact with
multiple pathways and reduce inflammatory biomarkers, thrombi
formation, and tissue damage to accelerate the patient outcome
(Schultz et al., 2021).
According to the literature, the interaction of host miRNA with
the COVID‐19‐encoded mRNAs may alter by age, underlying chronic
disease (diabetes, lung, and cardiovascular disorders), and gender.
Also, the ACE2, TMPRSS2, and ADAM17 genes might serve as po-
tent targets in patients with COVID‐19. However, more investiga-
tions are needed to confirm their interactions with miRNAs in
COVID‐19 and in other infectious events.
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